Phase 2 Ovarian Cancer Trial, Recruiting NCT07229040 Sponsor: Hospital General Universitario Gregorio Marañon Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT07229040
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who are female and between 18 and 75 years old.
  • People whose general health and ability to carry out daily activities meets a recognised medical scoring standard (a score of 2 or lower on the ECOG scale, which means the person is reasonably active and able to care for themselves).
  • People whose blood test results — including haemoglobin, white blood cells, neutrophils, and platelets — are within or close to the normal range, and whose kidney and liver function results are also acceptable.
  • People who have been assessed by an anaesthesiology (anaesthesia) team and considered fit to undergo major surgery.
  • People who have signed a form confirming they agree to take part in the trial.
  • People whose cancer is contained within the abdomen, with no spread to the lungs, bones, or other distant parts of the body. Cases with limited spread to the spleen or liver through the bloodstream may also be considered, as may cases with certain types of lymph node involvement inside the abdomen, where complete surgical removal appears possible.
  • People with a specific advanced stage of ovarian cancer (FIGO stage IVA) involving fluid around the lungs or certain lymph node or splenic spread, where chemotherapy given before surgery has produced a response — in these cases, the surgical treatment (CRS + HIPEC) may be considered afterwards.
  • People whose case has been reviewed by a multidisciplinary medical team, which has assessed the extent of disease and estimated that complete surgical removal is likely to be achievable.

Who may not be able to join:

  • People who have not given their consent to take part in the trial.
  • People whose general health or activity level falls below the required threshold (an ECOG score above 2, meaning significant limitation in daily activity).
  • People who are not considered suitable to undergo major surgery.
  • People whose cancer has spread beyond the abdomen, or where medical findings suggest that complete surgical removal would not be achievable — for example, if there is blockage of the bowel, bile ducts, or ureters, or widespread involvement of the small bowel or its surrounding tissue.
  • People with a known allergy or sensitivity to platinum-based chemotherapy drugs.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +34914265115

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Hospital General Universitario Gregorio Marañon
Registry
ClinicalTrials.gov
Start date
21 February 2025
Est. completion
21 October 2028

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Percentage of patients with renal failure at 7 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov